Publikationen von Grivas, Petros

Einerhand, Sarah M. H., Black, Anna J., Zargar, Homayoun , Fairey, Adrian S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobson, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil , Yu, Evan Y., Xylinas, Evanguelos, Kassouf, Wassim, Dall’Era, Marc A., Sridhar, Srikala S., McGrath, Jonathan S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M. , Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Daneshmand, Siamak, Zargar-Shoshtari, Kamran, Spiess, Philippe E., van Rhijn, Bas W. G., Black, Peter C. und Mertens, Laura S. (2022) Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology 40 (11), S. 2707-2715. Volltext nicht vorhanden.

Pal, Sumanta K, Somford, Diederik M, Grivas, Petros, Sridhar, Srikala S, Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T, Lerner, Seth P, Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P, Andresen, Corina, Schnabel, Marco J, Cole, Suzanne und Daneshmand, Siamak (2022) Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology 18 (21), S. 2599-2614. Volltext nicht vorhanden.